| First Author | Plotnikov A | Year | 2006 |
| Journal | Prostate | Volume | 66 |
| Issue | 15 | Pages | 1620-30 |
| PubMed ID | 16941466 | Mgi Jnum | J:115958 |
| Mgi Id | MGI:3692504 | Doi | 10.1002/pros.20435 |
| Citation | Plotnikov A, et al. (2006) Effective treatment of mouse metastatic prostate cancer by low electric field enhanced chemotherapy. Prostate 66(15):1620-30 |
| abstractText | BACKGROUND: We developed a new anti-cancer treatment, which is a combination of chemotherapeutic agents and low electric field. In the present study we investigated its efficacy against prostate metastatic transgenic adenocarcinoma of mice (TRAMP). METHODS: Mice with 5, 10, and 13 mm in diameter intracutaneous tumors received Low Electric Field Cancer Treatment-Enhanced Chemotherapy (LEFCT-EC) with doxorubicin (10 mg/kg), and monitored for survival, and primary and metastatic tumors growth. RESULTS: The electric field increased the uptake of doxorubicin by TRAMP cells in vitro. In vivo use of LEFCT-EC reduced tumor size, prolonged survival, and cured 36-93% of the animals, dependent on treated tumor size. LEFCT-EC was more effective than surgery with or without chemotherapy. Part of the cured animals developed anti-tumor immunity and immunosuppression, significantly decreased the effectiveness of the treatment. CONCLUSION: Our results suggest that LEFCT-EC is an effective method for the destruction of metastatic prostate tumors. |
